Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | YARS1 | P54577 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10885518 | 1.00 | SLC7A5 (0.59) | SLC7A5MMP2TAAR1SLC6A2LNPEP | |
| SCHEMBL9054297 | 0.87 | SLC7A5 (0.56) | SLC7A5MMP2 | |
| SCHEMBL13972848 | 0.87 | CSK (0.46) | SLC7A5MMP2LNPEPERAP2 | |
| SCHEMBL13382056 | 0.85 | MMP2 (0.56) | SLC7A5MMP2 | |
| SCHEMBL6653906 | 0.85 | ALPI (0.59) | SLC7A5MMP2 | |
| SCHEMBL988104 | 0.85 | ALPI (0.59) | SLC7A5MMP2 | |
| SCHEMBL25080948 | 0.84 | CHRND (0.56) | — | |
| SCHEMBL19102898 | 0.84 | SLC7A5 (0.53) | SLC7A5MMP2LNPEPERAP2YARS1 | |
| SCHEMBL10974111 | 0.84 | SLC7A5 (0.60) | SLC7A5MMP2LNPEPERAP2YARS1 | |
| SCHEMBL8975673 | 0.84 | SLC7A5 (0.60) | SLC7A5MMP2LNPEPERAP2YARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-8034365-B2 | Polymer substituted with amide or thioamide groups; vascular stents, bioreabsorbable polymers | REVA MEDICAL, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080112999-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | SLC7A5 3768/4885MMP2 4267/4885TAAR1 596/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | SLC7A5 3306/4885MMP2 1347/4885TAAR1 4451/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | SLC7A5 4451/4885MMP2 4412/4885TAAR1 1789/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | SLC7A5 3306/4885MMP2 1347/4885TAAR1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.